(3-methyloxetan-3-yl)methyl 10-bromodecanoate | 1208238-87-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (3-methyloxetan-3-yl)methyl 10-bromodecanoate
• CAS: 1208238-87-2
• 化学式: C₁₅H₂₇BrO₃
• 分子量: 335.282
• InChiKey: ANXBVQDHCKMFBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  19
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3-methyloxetan-3-yl)methyl 10-bromodecanoate 在 lithium aluminium tetrahydride 、 三氟化硼乙醚 、 对甲苯磺酸 、 magnesium 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 1,2-二溴乙烷 为溶剂， 反应 15.0h， 生成 (14Z,17Z,20Z,23Z,26Z,29Z)-dotriaconta-14,17,20,23,26,29-hexaenoic acid
  参考文献：
  名称：

  超长链多不饱和脂肪酸（VLC-PUFA）32:6 n-3的合成

  摘要：

  本文介绍了 VLC-PUFA 32:6 n-3、D 2标记的 32:6 n-3 的合成，以及 32:6 n-3 进入小鼠视网膜组织的过程。

  DOI：

  10.1039/d1ob00491c
• 作为产物：
  描述：

  10-溴癸酸 在 草酰氯 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 (3-methyloxetan-3-yl)methyl 10-bromodecanoate
  参考文献：
  名称：

  超长链多不饱和脂肪酸（VLC-PUFA）32:6 n-3的合成

  摘要：

  本文介绍了 VLC-PUFA 32:6 n-3、D 2标记的 32:6 n-3 的合成，以及 32:6 n-3 进入小鼠视网膜组织的过程。

  DOI：

  10.1039/d1ob00491c

文献信息

• Multi-arm polymeric alkanoate conjugates
  申请人：NEKTAR THERAPEUTICS

  公开号：US09220790B2

  公开（公告）日：2015-12-29

  Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies.

  本文提供了包含烷酸酯连接剂的多臂聚合物共轭物，包含这种共轭物的组合物，以及制备和给药这些共轭物的相关方法。还提供了使用这种共轭物进行治疗的方法和相关用途。这些共轭物具有高药物装载效率。
• [EN] RETINAL BIOAVAILABILITY OF SYNTHETIC VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS<br/>[FR] BIODISPONIBILITÉ RÉTINIENNE D'ACIDES GRAS POLYINSATURÉS À TRÈS LONGUE CHAÎNE SYNTHÉTIQUES
  申请人：UNIV UTAH RES FOUND

  公开号：WO2021257636A1

  公开（公告）日：2021-12-23

  The rare non-dietary very-long-chain polyunsaturated fatty acids (VLC-PUFAs) uniquely found in retina and a few other tissues play a clinically significant role in retinal degeneration and development, but their physiological and interventional research has been hampered by scarcity of pure VLC-PUFAs. Disclosed herein are methods of making fatty acids, including VLC-PUFAs, and methods of using these fatty acids in, for example, treating eye disorders and supplementing the diet of a female subject who is pregnant, desiring to become pregnant, or lactating. Also disclosed are compositions containing fatty acids and methods of making and using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  罕见的非膳食非常长链多不饱和脂肪酸（VLC-PUFAs）独特地存在于视网膜和少数其他组织中，在视网膜退化和发育中发挥着临床重要作用，但由于纯度不足的限制，它们的生理和干预研究受到了阻碍。本文披露了制备脂肪酸（包括VLC-PUFAs）的方法，以及利用这些脂肪酸治疗眼部疾病和补充怀孕、希望怀孕或哺乳的女性受试者饮食的方法。还披露了含有脂肪酸的组合物以及制备和使用这些组合物的方法。本摘要旨在作为在特定领域搜索的扫描工具，并不打算限制本发明。
• Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer
  作者：Pijus Saha、Sébastien Fortin、Valérie Leblanc、Sophie Parent、Éric Asselin、Gervais Bérubé

  DOI：10.1016/j.steroids.2012.06.004

  日期：2012.9

  Doxorubicin (DOX) is an important medicine for the treatment of breast cancer, which is the most frequently diagnosed and the most lethal cancer in women worldwide. However, the clinical use of DOX is impeded by serious toxic effects such as cardiomyopathy and congestive heart failure. Covalently linking DOX to estrogen to selectively deliver the drug to estrogen receptor-positive (Er) cancer tissues is one of the strategies under investigation for improving the efficacy and decreasing the cardiac toxicity of DOX. However, conjugation of drug performed until now was at 3- or 17-position of estrogen, which is not ideal since the hydroxyl groups at this position are important for receptor binding affinity. In this study, we designed, prepared and evaluated in vitro the first estrogen-doxorubicin conjugates at 16 alpha-position of estradiol termed E-DOXs (8a-d). DOX was conjugated using a 3-9 carbon atoms alkylamide linking arm. E-DOXs were prepared from estrone using a seven-step procedure to afford the desired conjugates in low to moderate yields. The antiproliferative activities of the E-DOX 8a conjugate through a 3-carbon spacer chain on ER+ MCF7 and HT-29 are in the micromolar range while inactive on M21 and the ER- MDA-MB-231 cells (>50 mu M). Compound 8a exhibits a selectivity ratio (ER+/ER- cell lines) of >3.5. Compounds 8b-8d bearing alkylamide linking arms ranging from 5 to 9 carbon atoms were inactive at the concentrations tested (>50 mu M). Interestingly, compounds 8a-8c exhibited affinity for the estrogen receptor alpha (ER alpha) in the nanomolar range (72-100 nM) whereas compound 8d exhibited no affinity at concentrations up to 215 nM. These results indicate that a short alkylamide spacer is required to maintain both antiproliferative activity toward ER+ MCF7 and affinity for the ER alpha of the E-DOX conjugates. Compound 8a is potentially a promising conjugate to target ER. breast cancer and might be useful also for the design of more potent E-DOX conjugates. (C) 2012 Elsevier Inc. All rights reserved.